Status:
ACTIVE_NOT_RECRUITING
Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II
Lead Sponsor:
Karen-Lise Garm Spindler
Collaborating Sponsors:
Herlev Hospital
Zealand University Hospital
Conditions:
Anal Cancer
Radiotherapy Side Effect
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study proposal includes a prospective clinical trial of bone sparing treatment planning in anal cancer patients. the trial aim to lower the risk of bone damage, while adhering with the constrains...
Detailed Description
Patients will receive standard (chemo)-radiotherapy according to national Danish Anal Cancer Group (DACG) guidelines, but the bone-sparing focus will be added to the algorithm for dose-constrains and ...
Eligibility Criteria
Inclusion
- Patients with biopsy verified localized squamous cell anal cancer
- Indication for standard (chemo)-radiotherapy with curative intend for anal cancer as per multidisciplinary team decision
- Clinical eligible for standard (chemo)-radiotherapy as per physicians' decision
- Written and oral consent
- Age at least 18 years
Exclusion
- Previous pelvic radiotherapy
- Previous systemic therapy with severe bone marrow suppression or hematological diseases
- Hip-replacements
- Contraindications to MRI-scan
Key Trial Info
Start Date :
August 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05385250
Start Date
August 23 2021
End Date
March 1 2026
Last Update
August 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8200